Horizon Global Corporation

The Canadian banking giant has a solid foundation on which it is building a much bigger business.

Related tickers: TD, BAC, COWN, HZN.

Gainers Horizon Global Corporation (NYSE: HZN) shares surged 341% to $1.7161 after the company announced it will be acquired by First Brands Group. Jasper Therapeutics, Inc. (NASDAQ: JSPR) gained 257% to $1.70 after the company announced clinical data from a Phase I/II trial of briquilimab as a conditioning treatment in sickle cell disease and beta thalassemia. ReShape Lifesciences Inc. (NASDAQ: RSLS) shares jumped 142.3% to $16.34. Reshape Lifesciences recently announced a 1-for-50 reverse stock split. Lucira Health, Inc. (NASDAQ: LHDX) surged 68% to $0.1875 after the company announced it submitted an Emergency Use Authorization application to the FDA for OTC use of its COVID-19 & Flu test. Swvl Holdings Corp. (NASDAQ: SWVL) shares gained 43% to $0.1958 after the company reported commencement of strategic review process. Vivos Therapeutics, Inc. (NASDAQ: VVOS) jumped 41% to $0.5678. Vivos Therapeutics recently posted a Q3 loss of $0.26 per share. EpicQuest Education Group International Limited (NASDAQ: EEIQ) gained 40.1% to $3.0962. Scilex Holding Company (NASDAQ: SCLX) jumped 40.1% to $5.59. Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) surged 33.8% to $0.6690. Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) gained 33.4% to $5.76. Aurinia said LUPKYNIS® (voclosporin) patent challenge settlement has been reached with Sun Pharmaceuticals. Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) rose 33.3% to $0.28. Navidea Biopharmaceuticals announced the notice of allowance for U.S. patent application for key component of the company's cancer immunotherapy pipeline. Chemomab Therapeutics Ltd. (NASDAQ: CMMB) gained 32% to $4.24 after the company reported top-line results from the CM-101 Phase 2a liver fibrosis biomarker trial in NASH patients. The trial met its primary endpoint. RedHill Biopharma Ltd. (NASDAQ: RDHL) jumped 29% to $0.1810 after the company announced publication of data from the Phase 2 data study of RHB-107 in non-hospitalized COVID-19 patients. The study met the primary endpoint of safety and tolerability. ACM Research, Inc. (NASDAQ: ACMR) gained 28.7% to $9.92 after the company issued FY23 revenue guidance above estimates. Checkpoint Therapeutics, Inc. ...

Related tickers: INTR, PRLD, NAAS, AUPH, SILO, GRRR, CLLS, ATNF, ACMR, GETR, HZN, VVOS, KEP, RTC, GDS, PALI, NU, LI, LHDX, SCLX, COSM, CMMB, TSLA, CKPT, EEIQ, NAVB, BIVI, BOXD, IDAI, NVOS, DRMA, IMCC, RDHL, KALA, ARQQ, GLMD, RSLS, ARBK, DADA, BILI, JSPR, TUSK, TBLT, MULN, SRNE, PDSB, SWVL, VLN, XPEV, SOUN.